Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 20, 2020
Daily News
May 20, 2020
- Label Revisions Ordered for 15 Insulins, Erleada, Faslodex
May 20, 2020
- JCR Chief Delays Global Licensing Timeline for Lysosomal Storage Disorder Therapies
May 20, 2020
- Astellas Confident of Hitting 3-Year Biz Goals on Xtandi, Full Backing of New Products
May 20, 2020
- MHLW Adds Veklury in Updated COVID-19 Treatment Guide
May 20, 2020
- LDP Lawmakers Call for Environment to Facilitate Vaccine Development
May 20, 2020
- Stella Pharma Launches New Cancer Radiation Therapy Steboronine
May 20, 2020
- Sawai, Nichi-Iko Hint at Delay in Edirol Generic Debut
May 20, 2020
- Astellas Eases Work-from-Home Policy in 39 Prefectures after Partial COVID-19 Emergency Lift
May 20, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…